Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + Carboplatin in Solid Tumors and HPV+ SCC
NCT05472220Phase 1Withdrawn
- Sponsor
- Alessa Therapeutics
- Start
- Nov 2022
- Primary completion
- Apr 2028
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of alpelisib in solid tumor and squamous cell carcinoma (SCC) (2 arms), sponsored by Alessa Therapeutics. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase 2 Dose at 21 days and 3 more. Planned start Nov 2022; status: withdrawn.
02
Drugs
alpelisib
03
Conditions
solid tumorsquamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT05472220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472220.